Recruiting studies: Follicular Helper T Cell Lymphoma Angioimmunoblastic Type

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphoma
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT07278856 Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Speci
Phase 3 · 34 location(s) · Corvus Pharmaceuticals, Inc. · NCT06561048 A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma W
Phase 3 · 44 location(s) · SecuraBio · NCT06522737 Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With P
Phase 3 · 158 location(s) · Eastern Cooperative Oncology Group · NCT06724237

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.